Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach

Aim The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a sentinel approach, thereby standardising and harmonising practices, and improving decision making around sentinel dosing. Sentinel dosing...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of clinical pharmacology Vol. 91; no. 9; pp. 2705 - 2710
Main Authors:	Heuberger, Jules A. A. C., Jongh, Perry, Hoogdalem, Ewoud‐Jan, Tamminga, Wim, Graeff, Pieter, Groeneveld, Geert Jan
Format:	Journal Article
Language:	English
Published:	England John Wiley and Sons Inc 01.09.2025
Subjects:	Algorithms Clinical Trials, Phase I as Topic - methods Clinical Trials, Phase I as Topic - standards Decision Making Decision Trees Dose-Response Relationship, Drug drug development first‐in‐human Humans Netherlands Original regulation Research Design sentinel dosing study design Netherlands drug development sentinel dosing regulation study design first‐in‐human
ISSN:	0306-5251, 1365-2125, 1365-2125
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Aim The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a sentinel approach, thereby standardising and harmonising practices, and improving decision making around sentinel dosing. Sentinel dosing is an approach described in EMA guidelines; however, the guidance does not provide detail on which cohorts or dose levels sentinel dosing applies. Methods This algorithm was designed using the expertise of senior scientific staff from the largest clinical research organisations in the Netherlands and after consultation with members of the ethics committee handling most early phase clinical drug trials in the Netherlands. Results The algorithm describes a decision tree considering different aspects of the design of the trial, the IMP, and the prior knowledge of the IMP based on (pre)clinical data, to be used by investigators and regulators. Hereby the decision‐making process on sentinel cohorts will be tailored to the specific IMP and information available. Starting in 2024, all three expert Phase 1 units that co‐authored this paper are using the algorithm as guidance for decision‐making on the implementation of sentinels in trials that are submitted to the EC Stichting BEBO. Conclusion The algorithm provides further guidance and specification on when to implement sentinel dosing in early phase clinical trials, thereby creating a standardised and harmonised approach, which will improve the protection of subject safety and trial efficiency.
AbstractList	The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a sentinel approach, thereby standardising and harmonising practices, and improving decision making around sentinel dosing. Sentinel dosing is an approach described in EMA guidelines; however, the guidance does not provide detail on which cohorts or dose levels sentinel dosing applies.AIMThe aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a sentinel approach, thereby standardising and harmonising practices, and improving decision making around sentinel dosing. Sentinel dosing is an approach described in EMA guidelines; however, the guidance does not provide detail on which cohorts or dose levels sentinel dosing applies.This algorithm was designed using the expertise of senior scientific staff from the largest clinical research organisations in the Netherlands and after consultation with members of the ethics committee handling most early phase clinical drug trials in the Netherlands.METHODSThis algorithm was designed using the expertise of senior scientific staff from the largest clinical research organisations in the Netherlands and after consultation with members of the ethics committee handling most early phase clinical drug trials in the Netherlands.The algorithm describes a decision tree considering different aspects of the design of the trial, the IMP, and the prior knowledge of the IMP based on (pre)clinical data, to be used by investigators and regulators. Hereby the decision-making process on sentinel cohorts will be tailored to the specific IMP and information available. Starting in 2024, all three expert Phase 1 units that co-authored this paper are using the algorithm as guidance for decision-making on the implementation of sentinels in trials that are submitted to the EC Stichting BEBO.RESULTSThe algorithm describes a decision tree considering different aspects of the design of the trial, the IMP, and the prior knowledge of the IMP based on (pre)clinical data, to be used by investigators and regulators. Hereby the decision-making process on sentinel cohorts will be tailored to the specific IMP and information available. Starting in 2024, all three expert Phase 1 units that co-authored this paper are using the algorithm as guidance for decision-making on the implementation of sentinels in trials that are submitted to the EC Stichting BEBO.The algorithm provides further guidance and specification on when to implement sentinel dosing in early phase clinical trials, thereby creating a standardised and harmonised approach, which will improve the protection of subject safety and trial efficiency.CONCLUSIONThe algorithm provides further guidance and specification on when to implement sentinel dosing in early phase clinical trials, thereby creating a standardised and harmonised approach, which will improve the protection of subject safety and trial efficiency. The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a sentinel approach, thereby standardising and harmonising practices, and improving decision making around sentinel dosing. Sentinel dosing is an approach described in EMA guidelines; however, the guidance does not provide detail on which cohorts or dose levels sentinel dosing applies. This algorithm was designed using the expertise of senior scientific staff from the largest clinical research organisations in the Netherlands and after consultation with members of the ethics committee handling most early phase clinical drug trials in the Netherlands. The algorithm describes a decision tree considering different aspects of the design of the trial, the IMP, and the prior knowledge of the IMP based on (pre)clinical data, to be used by investigators and regulators. Hereby the decision-making process on sentinel cohorts will be tailored to the specific IMP and information available. Starting in 2024, all three expert Phase 1 units that co-authored this paper are using the algorithm as guidance for decision-making on the implementation of sentinels in trials that are submitted to the EC Stichting BEBO. The algorithm provides further guidance and specification on when to implement sentinel dosing in early phase clinical trials, thereby creating a standardised and harmonised approach, which will improve the protection of subject safety and trial efficiency. Aim The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a sentinel approach, thereby standardising and harmonising practices, and improving decision making around sentinel dosing. Sentinel dosing is an approach described in EMA guidelines; however, the guidance does not provide detail on which cohorts or dose levels sentinel dosing applies. Methods This algorithm was designed using the expertise of senior scientific staff from the largest clinical research organisations in the Netherlands and after consultation with members of the ethics committee handling most early phase clinical drug trials in the Netherlands. Results The algorithm describes a decision tree considering different aspects of the design of the trial, the IMP, and the prior knowledge of the IMP based on (pre)clinical data, to be used by investigators and regulators. Hereby the decision‐making process on sentinel cohorts will be tailored to the specific IMP and information available. Starting in 2024, all three expert Phase 1 units that co‐authored this paper are using the algorithm as guidance for decision‐making on the implementation of sentinels in trials that are submitted to the EC Stichting BEBO. Conclusion The algorithm provides further guidance and specification on when to implement sentinel dosing in early phase clinical trials, thereby creating a standardised and harmonised approach, which will improve the protection of subject safety and trial efficiency.
Author	Heuberger, Jules A. A. C. Tamminga, Wim Hoogdalem, Ewoud‐Jan Graeff, Pieter Groeneveld, Geert Jan Jongh, Perry
AuthorAffiliation	1 Centre for Human Drug Research Leiden CL The Netherlands 2 ICON plc Groningen BM The Netherlands 5 Leiden University Medical Centre Leiden ZG The Netherlands 3 CTC Netherlands Groningen The Netherlands 4 Stichting Beoordeling Ethiek Biomedisch Onderzoek Assen ET The Netherlands
AuthorAffiliation_xml	– name: 1 Centre for Human Drug Research Leiden CL The Netherlands – name: 2 ICON plc Groningen BM The Netherlands – name: 5 Leiden University Medical Centre Leiden ZG The Netherlands – name: 3 CTC Netherlands Groningen The Netherlands – name: 4 Stichting Beoordeling Ethiek Biomedisch Onderzoek Assen ET The Netherlands
Author_xml	– sequence: 1 givenname: Jules A. A. C. orcidid: 0000-0001-7202-5088 surname: Heuberger fullname: Heuberger, Jules A. A. C. email: jheuberger@chdr.nl organization: Centre for Human Drug Research – sequence: 2 givenname: Perry surname: Jongh fullname: Jongh, Perry organization: ICON plc – sequence: 3 givenname: Ewoud‐Jan surname: Hoogdalem fullname: Hoogdalem, Ewoud‐Jan organization: ICON plc – sequence: 4 givenname: Wim surname: Tamminga fullname: Tamminga, Wim organization: CTC Netherlands – sequence: 5 givenname: Pieter surname: Graeff fullname: Graeff, Pieter organization: Stichting Beoordeling Ethiek Biomedisch Onderzoek – sequence: 6 givenname: Geert Jan orcidid: 0000-0002-4655-6667 surname: Groeneveld fullname: Groeneveld, Geert Jan email: ggroeneveld@chdr.nl organization: Leiden University Medical Centre
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/40370057$$D View this record in MEDLINE/PubMed
BookMark	eNp1kc1u1DAUhS1URKeFBS-AvIRFWv_EmRk2qB1BQaoEErC2nOs7icGxg51QzXvwwLidKQIEK_vqfucc6Z4TchRiQEKecnbGGRPnLYxnS8bW7AFZcNmoSnChjsiCSdZUSih-TE5y_sIYl7xRj8hxzWTh1XJBfnzEMLmAntqYXehe0gs6pjjGjJYa38Xkpn6gU6Td7CxSi-Cyi4EO5mvBafnd9A56CrGPacrUBYom-R0de5ORgnfBgfG3YxoMRB-7HZ2SMz7T3MfZWzoXbupdpmYs0Qb6x-ThtuzxyeE9JZ_fvP60eVtdv796t7m4rqDmK1ZZvoZm1S4BjFUN1kIsDbStEoKtuVVKNdBuFVcGecsFwLJmdl3mZguIUqA8Ja_2vuPcDmihnCIZr8fkBpN2Ohqn_9wE1-suftdcyBVv-Ko4PD84pPhtxjzpwWVA703AOGctBaul5Eqqgj77PexXyn0XBTjfA5Bizgm3GtxkpnLsku285kzftq1L2_qu7aJ48Zfi3vRf7MH9xnnc_R_Ul5sPe8VPwAC9CA
CitedBy_id	crossref_primary_10_1002_bcp_70154
Cites_doi	10.1177/0192623309332997 10.1111/cts.12437 10.1111/bcp.12920 10.1111/bph.15542 10.1038/nbt0506‐493 10.1111/bph.15537 10.1002/jcph.995 10.1016/S0140-6736(06)69562-7 10.1038/nbt0506‐475 10.1056/NEJMoa063842
ContentType	Journal Article
Copyright	2025 The Author(s). published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. 2025 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Copyright_xml	– notice: 2025 The Author(s). published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. – notice: 2025 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
DBID	24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM
DOI	10.1002/bcp.70090
DatabaseName	Open Access: Wiley-Blackwell Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: 24P name: Wiley-Blackwell Open Access Collection url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate	Heuberger et al
EISSN	1365-2125
EndPage	2710
ExternalDocumentID	PMC12381618 40370057 10_1002_bcp_70090 BCP70090
Genre	article Journal Article
GeographicLocations	Netherlands
GeographicLocations_xml	– name: Netherlands
GroupedDBID	--- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7X8 5PM
ID	FETCH-LOGICAL-c4180-d19c68b7ccad56e4227acbb522091d5556cbf515ae1b12cc740d95156fcee32e3
IEDL.DBID	24P
ISICitedReferencesCount	1
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001488016900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0306-5251 1365-2125
IngestDate	Tue Nov 04 02:05:39 EST 2025 Sat Nov 01 14:39:55 EDT 2025 Wed Sep 03 02:08:43 EDT 2025 Tue Nov 18 22:10:12 EST 2025 Sat Nov 29 07:35:43 EST 2025 Wed Aug 27 10:01:54 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	drug development sentinel dosing regulation study design first‐in‐human
Language	English
License	Attribution-NonCommercial http://creativecommons.org/licenses/by-nc/4.0 2025 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4180-d19c68b7ccad56e4227acbb522091d5556cbf515ae1b12cc740d95156fcee32e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-4655-6667 0000-0001-7202-5088
OpenAccessLink	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbcp.70090
PMID	40370057
PQID	3204331535
PQPubID	23479
PageCount	6
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_12381618 proquest_miscellaneous_3204331535 pubmed_primary_40370057 crossref_citationtrail_10_1002_bcp_70090 crossref_primary_10_1002_bcp_70090 wiley_primary_10_1002_bcp_70090_BCP70090
PublicationCentury	2000
PublicationDate	September 2025
PublicationDateYYYYMMDD	2025-09-01
PublicationDate_xml	– month: 09 year: 2025 text: September 2025
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: Hoboken
PublicationTitle	British journal of clinical pharmacology
PublicationTitleAlternate	Br J Clin Pharmacol
PublicationYear	2025
Publisher	John Wiley and Sons Inc
Publisher_xml	– name: John Wiley and Sons Inc
References	2007 2017 2016 2016; 81 2006; 24 2006; 368 2021; 178 2009; 37 2017; 10 2017; 57 2006; 355 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 Council for International Organizations of Medical Sciences (e_1_2_9_2_1) e_1_2_9_9_1 e_1_2_9_15_1 e_1_2_9_14_1
References_xml	– volume: 10 start-page: 122 issue: 3 year: 2017 end-page: 123 article-title: Take Care of the Fast‐in‐Human Study publication-title: Clin Transl Sci – volume: 355 start-page: 1018 issue: 10 year: 2006 end-page: 1028 article-title: Cytokine storm in a phase 1 trial of the anti‐CD28 monoclonal antibody TGN1412 publication-title: N Engl J Med – volume: 368 start-page: 1387 year: 2006 end-page: 1391 article-title: Establishing risk of human experimentation with drugs: lessons from TGN1412 publication-title: Lancet – volume: 24 start-page: 493 issue: 5 year: 2006 end-page: 496 article-title: TGN1412—a regulator's perspective publication-title: Nat Biotechnol – year: 2007 – volume: 37 start-page: 363 issue: 3 year: 2009 end-page: 371 article-title: The EMEA guideline on first‐in‐human clinical trials and its impact on pharmaceutical development publication-title: Toxicol Pathol – volume: 57 start-page: 1357 issue: 10 year: 2017 end-page: 1358 article-title: The use of IC(50) for potency and MTD as objective in study BIA 10–2474 publication-title: J Clin Pharmacol – volume: 81 start-page: 582 issue: 4 year: 2016 end-page: 586 article-title: Implications of the BIA‐102474‐101 study for review of first‐into‐human clinical trials publication-title: Br J Clin Pharmacol – year: 2017 – year: 2016 – volume: 24 start-page: 475 issue: 5 year: 2006 end-page: 476 article-title: TeGenero fiasco prompts regulatory rethink publication-title: Nat Biotechnol [Internet] – volume: 178 start-page: S313 issue: S1 year: 2021 end-page: S411 article-title: The concise guide to pharmacology 2021/22: enzymes publication-title: Br J Pharmacol – volume: 178 start-page: S1 issue: S1 year: 2021 end-page: S26 article-title: The concise guide to pharmacology 2021/22: Introduction and other protein targets publication-title: Br J Pharmacol – ident: e_1_2_9_6_1 doi: 10.1177/0192623309332997 – ident: e_1_2_9_10_1 doi: 10.1111/cts.12437 – ident: e_1_2_9_12_1 doi: 10.1111/bcp.12920 – ident: e_1_2_9_14_1 doi: 10.1111/bph.15542 – ident: e_1_2_9_5_1 doi: 10.1038/nbt0506‐493 – ident: e_1_2_9_8_1 – ident: e_1_2_9_15_1 doi: 10.1111/bph.15537 – ident: e_1_2_9_11_1 doi: 10.1002/jcph.995 – volume-title: Safety requirements for the first use of new drugs and diagnostic agents in man ident: e_1_2_9_2_1 – ident: e_1_2_9_7_1 doi: 10.1016/S0140-6736(06)69562-7 – ident: e_1_2_9_9_1 – ident: e_1_2_9_13_1 – ident: e_1_2_9_4_1 doi: 10.1038/nbt0506‐475 – ident: e_1_2_9_3_1 doi: 10.1056/NEJMoa063842
SSID	ssj0013165
Score	2.4728854
Snippet	Aim The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ... The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a...
SourceID	pubmedcentral proquest pubmed crossref wiley
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	2705
SubjectTerms	Algorithms Clinical Trials, Phase I as Topic - methods Clinical Trials, Phase I as Topic - standards Decision Making Decision Trees Dose-Response Relationship, Drug drug development first‐in‐human Humans Netherlands Original regulation Research Design sentinel dosing study design
Title	Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbcp.70090 https://www.ncbi.nlm.nih.gov/pubmed/40370057 https://www.proquest.com/docview/3204331535 https://pubmed.ncbi.nlm.nih.gov/PMC12381618
Volume	91
WOSCitedRecordID	wos001488016900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2125 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqlgMX3tDlUQ0IVRwaGjt2nMCpFFYcqiqCFu0tSmynidQmq00W1P_BD2bsbLKsChISlyhRJrEjjzOfH_N9hLwWscj9nAqPK8Y9riPlRbE0XmhiX4mYZsrlwnw7kaen0WwWJ1vk_ZAL0_NDjBNutme4_7Xt4FneHq5JQ3M1fysRIeB4fYfSQFqXZjxZLyFQpyNpMTGOtgQdaIV8djg-uhmMbiDMmxslfwewLgJN7_5X3e-ROyvgCUe9p9wnW6Z-QPaTnrn6-gDO1olY7QHsQ7LmtL5-SH5-tbuKsFjQjZ1deAdHMLcCC63RkF1eNIuqK6-ga-BiWWkDeiXdA1dO7Qrw7EdZqRKsIO-ia6GqwVhuZZiXGEdhSNC0l2Ox4CRFWmhLq8MNS7Sz8skw8KA_IufTT2fHn72VoIOnOI18T9NYhVEu0Wu0CA1nTGYqzxECImrRQohQ5QUCrMzQnDKlJPc1IkARFhjKA2aCx2S7bmqzS0AWOCwowqwIqeK8YLFG7IZOoFUQZYbFE_JmaNlUrdjOrejGZdrzNLMU2yB1bTAhr0bTeU_x8Sejl4N7pNgB7apKVptm2aaBzS4OMHCICXnSu8v4Gu4H0qb7Tki04UijgSX33rxTV6Uj-aYWS4U0wg9xnvT3qqUfjhN38vTfTZ-R28wKGbvNcs_JdrdYmhfklvreVe1iz3UkPMpZtEd2Pn6Znp_8As7LJxQ
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLamDglexh06bgeEJh4WFjt2LoiXMaiGKFUFHdpblNjOEmlLqiYF7X_wgzl2mpRqICHx5ignsSMf53y-nO8j5KWIROqmVDhcMu5wFUonjALt-DpypYhoIm0uzLdxMJmEp6fRdIu87XJhWn6IfsHNjAz7vzYD3CxIH6xZQ1M5fx0gRMAJ-zZHNxIDsv3-y-hkvN5FoFZK0sBinHAJ2jELueygf3gzHl0BmVfPSv6OYW0QGt38v-bfIjsr8AmHrbfcJlu6vEP2pi179eU-zNbJWPU-7MF0zWt9eZf8_GpOFmG9oCqzwvAGDmFuRBZqrSA5P6sWRZNfQFPB2bJQGtRKvgcurOIVYOlHXsgcjCjvoqmhKEEbfmWY5xhLoUvSNJd9tWBlRWqoc6PFDUu0MxLK0HGh3yMnow-zo2NnJergSE5D11E0kn6YBug5SviaMxYkMk0RBiJyUUIIX6YZgqxE05QyKQPuKkSBws8wnHtMe_fJoKxK_ZBAkOHUIPOTzKeS84xFCvGbF0RKemGiWTQkr7qujeWK8dwIb5zHLVczi7EPYtsHQ_KiN523NB9_Mnre-UeMg9DsrCSlrpZ17JkMYw-DhxiSB62_9K_hrheYlN8hCTc8qTcwBN-bd8oit0Tf1OApn4b4IdaV_t60-N3R1BZ2_930Gbl-PPs8jscfJ58ekRvMCBvbw3OPyaBZLPUTck1-b4p68XQ1rn4BUY0qCQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtQwELWqghAvUO4LFAaEKh6aNnbsXKq-lMIKRLWKREF9ixLbaSK1SbTJgvoffDBjZ5NlVZCQeHOUSeLIY8_xZc4h5I2IROZmVDhcMu5wFUonjALt-DpypYhoKm0uzLeTYDYLz86ieIMcDrkwPT_EuOBmeoYdr00H143K91esoZls9gKECDhhv8EFjrGG15nHqz0EaoUkDSjG6ZagA6-Qy_bHR9ej0TWIef2k5O8I1oag6d3_q_wWubOEnnDU-8o9sqGr-2Qn7rmrr3bhdJWK1e7CDsQrVuurB-TnF3OuCL8LqjbrCwdwBI2RWGi1gvTivJ6XXXEJXQ3ni1JpUEvxHri0eleApR9FKQswkrzzroWyAm3YlaEpMJLCkKJpLsfPghUVaaEtjBI3LNDOCCjDwIT-kHydfjg9_ugsJR0cyWnoOopG0g-zAP1GCV9zxoJUZhmCQMQtSgjhyyxHiJVqmlEmZcBdhRhQ-DkGc49p7xHZrOpKPyEQ5DgxyP0096nkPGeRQvTmBZGSXphqFk3I26FpE7nkOzeyGxdJz9TMEmyDxLbBhLweTZue5ONPRq8G_0iwC5p9lbTS9aJNPJNf7GHoEBPyuPeX8TXc9QKT8Dsh4ZonjQaG3nv9TlUWluabGjTl0xB_xLrS36uWvDuObeHpv5u-JLfi99Pk5NPs8zNymxlVY3ty7jnZ7OYLvU1uyu9d2c5f2E71C2tLJ_I
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sentinel+dosing%3A+A+proposed+algorithm+to+guide+decision+making+on+which+cohorts+in+early+phase+clinical+pharmacology+trials+should+use+this+approach&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Heuberger%2C+Jules+A+A+C&rft.au=de+Jongh%2C+Perry&rft.au=van+Hoogdalem%2C+Ewoud-Jan&rft.au=Tamminga%2C+Wim&rft.date=2025-09-01&rft.issn=1365-2125&rft.eissn=1365-2125&rft.volume=91&rft.issue=9&rft.spage=2705&rft_id=info:doi/10.1002%2Fbcp.70090&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon